Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 11.25 CAD 0.45% Market Closed
Market Cap: 132.7m CAD
Have any thoughts about
Biosyent Inc?
Write Note

Relative Value

The Relative Value of one RX stock under the Base Case scenario is 8.45 CAD. Compared to the current market price of 11.25 CAD, Biosyent Inc is Overvalued by 25%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RX Relative Value
Base Case
8.45 CAD
Overvaluation 25%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
28
vs Industry
34
Median 3Y
3.4
Median 5Y
3.5
Industry
2.5
Forward
3.7
vs History
33
vs Industry
28
Median 3Y
16.2
Median 5Y
16.8
Industry
21.9
Forward
23
vs History
1
vs Industry
25
Median 3Y
18.5
Median 5Y
18.1
Industry
16.5
vs History
1
vs Industry
23
Median 3Y
20.1
Median 5Y
19.3
Industry
23.6
vs History
6
vs Industry
23
Median 3Y
2.9
Median 5Y
3.1
Industry
2.1
vs History
6
vs Industry
38
Median 3Y
2.4
Median 5Y
2.6
Industry
2.6
Forward
3.2
vs History
7
vs Industry
54
Median 3Y
3
Median 5Y
3.2
Industry
5.2
vs History
4
vs Industry
32
Median 3Y
9.1
Median 5Y
9.4
Industry
13.3
Forward
13.5
vs History
7
vs Industry
35
Median 3Y
9.7
Median 5Y
10
Industry
16.6
vs History
1
vs Industry
30
Median 3Y
13.5
Median 5Y
13
Industry
15.6
vs History
1
vs Industry
26
Median 3Y
13.7
Median 5Y
13.3
Industry
19.1
vs History
88
vs Industry
12
Median 3Y
8.5
Median 5Y
9
Industry
1.9

Multiples Across Competitors

RX Competitors Multiples
Biosyent Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Biosyent Inc
XTSX:RX
130.3m CAD 3.9 18.2 13 13.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
CA
Biosyent Inc
XTSX:RX
Average P/E: 30.6
18.2
19%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top